Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study

Jing Huang, Yingying Yang, Yongmei Wang, Sihang Jiang, Ying Zhang, Shimin Zhao, Shuang Wang, Bing Chen, Gang LiuFrontiers in Immunology 2025 · DOI

Abstract

Rituximab demonstrated non-inferior clinical remission rates at 12 months compared to CYC and CNIs. Rituximab was also associated with lower relapse rates and better safety profile. These findings suggest that rituximab offers distinct advantages in maintaining long-term clinical remission and may be considered an effective treatment regimen for IMN patients at risk of disease progression.

Introduction

Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in adults, often progressing to end-stage renal disease if left untreated. For decades, the "gold standard" treatments have involved heavy-hitting immunosuppressants: glucocorticoids (GC) combined with either cyclophosphamide (CYC) or calcineurin inhibitors (CNIs).

While effective, these conventional regimens are a double-edged sword. CYC carries risks of bone marrow suppression and infection, while CNIs are associated with high relapse rates upon discontinuation and potential nephrotoxicity. Rituximab (RTX), a monoclonal antibody targeting CD20+ B cells, offers a more targeted approach. Although the 2021 KDIGO guidelines include RTX, real-world comparative data—especially regarding long-term effectiveness and safety versus the "old guard"—has remained insufficient. This study seeks to fill that gap by evaluating the real-world performance of RTX monotherapy.

Methods

The researchers conducted a real-world retrospective study of 310 adult IMN patients diagnosed via renal biopsy at a single center in China between 2015 and 2023. Patients were divided into three cohorts based on their treatment background:

  • RTX Group (n=62): Received either 375 mg/m² weekly for four weeks or two 1g doses spaced two weeks apart.
  • GC+CYC Group (n=124): Traditional "Ponticelli-like" regimen involving steroids and cyclophosphamide.
  • GC+CNI Group (n=124): Steroids combined with Tacrolimus or Cyclosporine.

The primary endpoint was the clinical remission rate at 12 months. Secondary endpoints included remission and relapse rates at 24 months, as well as the occurrence of adverse events (AEs). The study utilized a primary clinical dataset including longitudinal measurements of proteinuria, serum albumin (ALB), serum creatinine, eGFR, and anti-PLA2R antibody titers.

Flowchart of IMN patients receiving three treatment regimens, detailing inclusion and exclusion criteria.

Key Results and Insights

Clinical Remission and the "Slow Burn" Advantage

At the 12-month mark, RTX appeared roughly equal to conventional therapies, proving non-inferiority. Clinical remission rates were 71.0% for RTX, 72.6% for GC+CYC, and 78.2% for GC+CNI. However, by 24 months, the RTX group’s remission rate climbed to 94.3%, significantly outperforming the other groups ($P = 0.002$). Furthermore, 24-month complete remission (CR) was significantly higher in the RTX group (51.4%) compared to GC+CYC (38.3%) and GC+CNI (41.2%). This suggests that RTX provides a more durable, sustained immunological response over time.

Biochemical Recovery

All three treatment groups showed a steady improvement in serum albumin (ALB) levels over the first 12 months of follow-up. This recovery in ALB is a critical indicator of resolving nephrotic syndrome and clinical response to therapy.

Follow-up of serum albumin (ALB) levels (g/l) over 12 months across the three treatment groups.

Safety as a Primary Differentiator

The most striking finding was the safety profile. Conventional regimens saw adverse event rates between 57.3% and 68.5%. In contrast, the RTX group had an AE rate of only 27.4%, with zero severe adverse events reported. Common issues in the conventional groups, such as hair loss, infection, and liver damage, were largely absent or significantly reduced in the RTX cohort.

Immunological Clearance

RTX was notably more effective at reducing anti-PLA2R antibody levels—the primary driver of IMN—to near-undetectable levels compared to GC+CYC or GC+CNI. This deeper "immunological remission" likely explains the lower relapse rates observed in the RTX group. Logistic regression identified the baseline anti-PLA2R antibody titer as an independent risk factor for non-remission, reinforcing the value of using antibody levels to tailor treatment intensity.

Conclusion

This retrospective study demonstrates that Rituximab monotherapy is non-inferior to traditional steroid-based regimens for treating IMN at 12 months and becomes significantly more effective by the 24-month mark. Crucially, RTX achieved these superior long-term remission rates with a substantially lower incidence of adverse events, positioning it as a safer, highly effective first-line alternative to conventional immunosuppression.

While limited by its retrospective, single-center design, these findings provide strong real-world evidence for the benefits of RTX. Future work should include larger, multicenter, randomized controlled trials to confirm these findings and refine individualized dosing strategies based on anti-PLA2R titers.

Summary updated

Abstract

Rituximab demonstrated non-inferior clinical remission rates at 12 months compared to CYC and CNIs. Rituximab was also associated with lower relapse rates and better safety profile. These findings suggest that rituximab offers distinct advantages in maintaining long-term clinical remission and may be considered an effective treatment regimen for IMN patients at risk of disease progression.
BibTeX
@inproceedings{huang2025effectiveness,
  author = {Jing Huang and Yingying Yang and Yongmei Wang and Sihang Jiang and Ying Zhang and Shimin Zhao and Shuang Wang and Bing Chen and Gang Liu},
  title = {{Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1671251},
}
Figure